Please use this identifier to cite or link to this item: http://hdl.handle.net/10609/146766
Title: Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection
Author: Prats, Anna  
Martínez Zalacaín, Ignacio
Mothe, Beatriz  
Negredo, Eugènia
Pérez Álvarez, Núria
Garolera, Maite  
Domènech Puigcerver, Sira
Coll, Pep  
Meulbroek, Michael  
Chamorro, Anna
Fumaz, Carmina R.  
Ferrer, Maria J.
Clotet, Bonaventura
Soriano-Mas, Carles  
Muñoz-Moreno, Jose A.  
Others: Hospital Universitari Germans Trias i Pujol
Clínica Teknon Grupo Quirón-Salud
Universitat Autònoma de Barcelona (UAB)
Hospital Universitari de Bellvitge
Universitat de Barcelona (UB)
Universitat de Vic
Universitat Politècnica de Catalunya (UPC)
Instituto de Salud Carlos III
Universitat Oberta de Catalunya (UOC)
Projecte dels NOMS - Hispanosida
Keywords: anxiety
central nervous system infections
cognitive neuroscience
depression
infectious diseases
Issue Date: 28-May-2021
Publisher: Scientific Reports
Citation: Prats, A., Martínez-Zalacaín, I., Mothe, B., Negredo, E., Pérez-Álvarez, N., Garolera, M., ... & Muñoz-Moreno, J. A. (2021). Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection. Scientific reports, 11(1), 1-9.
Published in: 11
Project identifier: info:eu-repo/grantAgreement/IFLS-ANT/2015-01
info:eu-repo/grantAgreement/FI17/00294
info:eu-repo/grantAgreement/CPII16/00048
Also see: https://doi.org/10.1038/s41598-021-90678-6
Abstract: Integrase strand transfer inhibitors (INSTI) are a main component of the current antiretroviral regimens recommended for treatment of HIV infection. However, little is known about the impact of INSTI on neurocognition and neuroimaging. We developed a prospective observational trial to evaluate the effects of INSTI-based antiretroviral therapy on comprehensive brain outcomes (cognitive, functional, and imaging) according to the time since HIV-1 acquisition. We recruited men living with HIV who initiated antiretroviral therapy with INSTI < 3 months since the estimated date of HIV-1 acquisition (n = 12) and > 6 months since estimated date of HIV-1 acquisition (n = 15). We also recruited a group of matched seronegative individuals (n = 15). Assessments were performed at baseline (before initiation of therapy in HIV arms) and at weeks 4 and 48. Baseline cognitive functioning was comparable between the arms. At week 48, we did not find cognitive differences between starting therapy with INSTI earlier than 3 months or later than 6 months after acquisition of HIV-1 infection. Functional status was poorer in individuals diagnosed earlier. This effect recovered 48 weeks after initiation of therapy. Regarding brain imaging, we found that men living with HIV initiating antiretroviral therapy later experienced a greater decrease in medial orbitofrontal cortex over time, with expected negative repercussions for decision-making tasks.
Language: English
URI: http://hdl.handle.net/10609/146766
ISSN: 2045-2322MIAR
Appears in Collections:Articles
Articles cientÍfics

Files in This Item:
File Description SizeFormat 
scientific reports-Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection.pdfEffects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection1,34 MBAdobe PDFThumbnail
View/Open
Share:
Export:
View statistics

Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.